Figure 3.

The expression score of < 2.85 and ≥ 2.85 were classified as low and high based on a receiver operating characteristic curve (area under the curve 0.632, 95% confidential interval 0.453-0.810). Associations between HDAC9 levels and disease-free survival in stage I lung adenocarcinomas were analyzed by the Log-rank test (P = 0.3552). Sixty-three patients were used for disease-free survival analysis. Kaplan-Meier survival curves are shown (five-year disease-free survival rates were 77.3% and 88.3% HADC9 low- and high-expressers, respectively.